AUS
NZ
UK
CA
USA
IND
On July 22, 2026, Vicky B. Gregg, a director at Quest Diagnostics Inc. (NYSE:DGX), purchased 72 shares of common stock through a dividend reinvestment plan managed by her broker. Reported on July 27, 2026, this transaction increased Gregg's total beneficial ownership to 18,386 shares. The shares were acquired at $206.808 each, reflecting an automatic dividend reinvestment at the diagnostic testing company.
Key Points
- NYSE: DGX
- Director Vicky B. Gregg acquired 72 shares on July 22, 2026, via dividend reinvestment plan
- Purchase price was $206.808 per share, raising total beneficial ownership to 18,386 shares
- Transaction was eligible for deferred reporting but was voluntarily disclosed early by the director
Director's Share Purchase Through Dividend Reinvestment Plan
Vicky B. Gregg, serving as a Quest Diagnostics director, acquired 72 common stock shares on July 22, 2026, at $206.808 per share. This purchase was executed under a dividend reinvestment plan administered by her broker, which automatically converts dividend payments into additional shares of Quest Diagnostics stock.
Although these shares qualified for deferred reporting under Rule 16a-6 on Form 5, Gregg opted for early disclosure by filing Form 4 on July 27, 2026, five days post-transaction. This proactive filing offers investors timely insight into insider ownership changes within the diagnostics firm.
Post-Transaction Beneficial Ownership Details
Following the acquisition, Gregg's direct beneficial ownership in Quest Diagnostics totals 18,386 shares. This figure represents her accumulated equity stake as a board member and excludes any derivative or indirect ownership interests.
Investors tracking insider ownership often view such changes as indicators of director confidence, although acquisitions via dividend reinvestment plans typically reflect routine capital management rather than active trading decisions.
Understanding the Dividend Reinvestment Transaction
Dividend reinvestment plans (DRIPs) automatically use dividend payouts to purchase additional company shares, enabling insiders like board members to grow their equity passively over time. In this case, Gregg's broker facilitated the reinvestment of her Quest Diagnostics dividends, resulting in the purchase of 72 new shares.
The transaction is considered routine wealth accumulation by insiders maintaining long-term holdings. Gregg’s choice to report early rather than defer demonstrates a commitment to transparency and regulatory compliance.
Regulatory Filing and Insider Reporting Obligations
This disclosure complies with Section 16(a) of the Securities Exchange Act of 1934, mandating officers, directors, and significant shareholders to report changes in beneficial ownership. Gregg’s timely Form 4 filing on July 27, 2026, satisfies these requirements.
Form 4 submissions must occur within two business days of a transaction. The filing lists Sean D. Mersten as Gregg’s attorney in fact, indicating authorized legal representation handled the submission, a common practice for insider reporting.
Monitoring Insider Ownership at Quest Diagnostics
Investors often review Form 4 filings to assess leadership investment patterns. Dividend reinvestment activity suggests insiders are maintaining or increasing stakes through passive accumulation rather than selling shares. However, such transactions differ in analytical significance compared to active open-market trades.
Over time, dividend reinvestment can notably increase an insider’s holdings. Gregg’s 18,386 shares reflect cumulative acquisitions and ongoing reinvestments. Analysts should consider both active and passive ownership changes when evaluating insider positions.
Transaction Price Context on July 22, 2026
The shares were acquired at $206.808 each, the value used by the dividend reinvestment plan on the transaction date. This price is mechanically determined by the plan’s administration and market conditions at dividend payment processing, differing from discretionary open-market purchase prices.
Understanding this price helps contextualize Gregg’s cost basis and the value of her holdings, though it does not reflect active market timing.
Direct Ownership and Future Reporting Responsibilities
Gregg holds all 18,386 shares in direct ownership, registered in her name or brokerage account, with no indirect ownership arrangements reported. As a director, she must continue filing Form 4 disclosures for any future beneficial ownership changes, whether from trading, compensation, or dividend reinvestment.
This ongoing reporting ensures transparency regarding board members’ equity interests and alignment with shareholder value.
Investor Insights on Insider Ownership Disclosures
Investors should differentiate between passive dividend reinvestment and active insider transactions when analyzing ownership changes. While Gregg’s filing does not indicate her investment outlook or confidence level, her cumulative 18,386-share stake is a minority position relative to Quest Diagnostics’ total equity.
Evaluating insider ownership trends across multiple leaders and over time provides deeper insight into management’s alignment with shareholder interests. Reviewing periodic proxy statements and beneficial ownership disclosures offers comprehensive context on insider participation at Quest Diagnostics.
